Conference Day Two - Thursday | April 18, 2024

8:00 am Morning Refreshments

8:25 am Chair’s Opening Remarks

  • Nimish Gera Vice President, Biologics, Mythic Therapeutics

Antibodies Ahead of the Curve: Developing Antibody Target Engagement & Fc-Mediated Function

8:30 am Biology-Guided Engineering of Antibody & Albumin Molecules

  • Jan Terje Andersen Professor in Biomedical Innovation | Research Group Leader | CoE Precision Immunotherapy Alliance (PRIMA), Oslo University | Oslo University Hospital

Synopsis

  • FcRn as a key homeostatic regulator of both IgG and albumin
  • Why considering large cross-species FcRn binding differences
  • Engineering of antibody and albumin formats with tailored binding and transport properties
  • Modulating transplacental transport of antibody and albumin designs

9:00 am Functional Evaluation of mAb Fc Modifications Dependent on In Vitro Incorporation of Physiological Relevant Variables – Enhancing Design Optimization

Synopsis

  • Influence of antibody target/epitope on the functional outcome of Fc engineering strategies
  • Importance of relevant factors (e.g. antigen binding, competing IgG) during the assessment of Fc engineering strategies
  • Translatability of human Fc engineering strategies to murine and cynomolgus Fc receptors

9:30 am Fc Silencing: How Much Silencing do we Really Need?

Synopsis

  • Determining IgG FcyRs binding and signalling profiles by cell-based assay
  • Evaluating the main Fc silencing mutations
  • What the specific needs are for silencing and how to understand the residual binding on FcgRs
  • Discussing FcR binding or silencing in vivo and biologics efficacy

10:00 am Severing Fc Effector Functions from Antigen Binding; IgG Proteases for Autoimmunity

Synopsis

  • Discussing bacterial IgG protease IdeS cleaving antibodies in the hinge to decouple effector functions from antigen binding
  • AI-guided removal of T cell epitopes and shielding of surface epitopes by glycoengineering to reduce Immunogenicity of IdeS 
  • Extending pharmacodynamics by hyperglycosylation, creating a long-lived deimmunized IgG protease for deactivation and depletion of IgG autoantibodies

10:30 am Morning Break & Networking

11:30 am Round table Discussions: Join Peer-Led Group Discussions to Crowdsource Insights and Enhance the Therapeutic Potency of Fc-Mediated Function

  • Rakesh Dixit President & Chief Scientific Officer, Regio Biosciences

On versus Off Target Effect: Enhancing Therapeutic Potency without Increasing Toxicity when Targeting FcRs

  • Rakesh Dixit President & Chief Scientific Officer, Regio Biosciences

Strategies to Tailor the PK of Biologics, with or without Effector Functions

  • Jan Terje Andersen Professor in Biomedical Innovation | Research Group Leader | CoE Precision Immunotherapy Alliance (PRIMA), Oslo University | Oslo University Hospital

Diversified FcR Interactions for Future Flexibility in Antibody Engineering

12:00 pm Antibody Ideas & Evolution: Surveying Interactions, Receptor Activity Modulation, & Drug Development

  • Rakesh Dixit President & Chief Scientific Officer, Regio Biosciences

Synopsis

  • Attaining better in-depth biological understanding to keep up with antibody evolution, and progress beyond assumptions towards a more comprehensive analysis of antibody functions
  • Looking at how to modify antibody architecture to adapt it based on cellular interactions, heightening antibody design, binding, and half-life extension
  • Expanding the design space of antibodies to modulate receptor activity and diversify application to achieve flexibility in antibody engineering

1:00 pm Lunch & Networking

Targeting FcyR in its Own Right – What is the Next Mutation?

2:00 pm “All Things Fc Gamma”: Harnessing the Potential of Fc Gamma Receptors to Tune Antibody-based Immunotherapy

Synopsis

  • Examining the beneficial or compromising effect of FcyRs in antibody-based cancer immunotherapies
  • Tailored FcgR-blockade to enhance the efficacy of therapeutic antibodies
  • Outlook inflammation – how FcgRs can be harnessed for the treatment of autoimmune and inflammatory disease

2:30 pm Unlocking Fc Gamma Receptors’ Power: Fine-Tuning Antibody-Based Immunotherapy Identification & Characterization of FcγRIIb Selective PD-1 Agonist mAbs

Synopsis

  • Agonist antibodies to PD-1 that mimic the function of natural ligands have the potential to suppress human autoimmune diseases and reinstate tolerance
  • PD-1 agonist antibodies rely on the mediated clustering of Fc-gamma receptors (FcγRs) to elicit their suppressive function
  • Seismic PD-1 agonist is a dual-cell bidirectional antibody that agonizes PD-1 and selectively binds the inhibitory FcγRIIb receptor
  • Seismic PD-1 agonist inhibits T-cell activity while preventing antigen presenting cell activation

3:00 pm Chair’s Closing Remarks

  • Nimish Gera Vice President, Biologics, Mythic Therapeutics